Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Effects of Hemoadsorption on Vascular Integrity in Septic Shock

NCT: NCT07711197 · NOT_YET_RECRUITING

NCT IDNCT07711197
StatusNOT_YET_RECRUITING
Start Date2026-09-01
Completion2029-01-01
SponsorSemmelweis University (OTHER)
First posted
Last updated

Brief Summary

This study aims to investigate the effects of adjunctive CytoSorb hemoadsorption therapy versus standard medical treatment on endothelial dysfunction in patients with refractory septic shock. The investigators hypothesize that hemoadsorption mitigates endothelial and glycocalyx injury by removing inflammatory mediators and other injurious circulating molecules, promoting hemodynamic stabilization.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑